ARDX - Accelerate Diagnostics rises 7% on commercialization of Accelerate Arc system for use in blood culture test

Accelerate Diagnostics (NASDAQ:ARDX) is trading 7.2% higher after the company announced on Monday the commercialization of its new Accelerate Arc Module and BC (blood culture) kit for accurate microbial identification for positive blood cultures. The company said the Accelerate Arc system cuts hours of wait time, eliminates laborious hands-on sample prep, and offers significant cost savings for healthcare facilities compared to current methods. The product requires 2-3 minutes to run In March, the company launched Accelerate Arc system, comprising of Arc Module and BC kit.

For further details see:

Accelerate Diagnostics rises 7% on commercialization of Accelerate Arc system for use in blood culture test